ECO 2026: REDEFINE-1 demonstrates CagriSema's improvement in body composition - Pharmaceutical Technology

Data from the REDEFINE-1 trial (NCT05567796) were recently presented in Türkiye, assessing Novo Nordisk's CagriSema in adults with obesity. This analysis aimed to evaluate muscle strength, changes in body composition assessed by dual-energy DXA, and the correlation between body composition and physical function. Credit: Kittyfly / Shutterstock.com. On 12 May 2026, at the 33rd European Congress on Obesity in Istanbul, Türkiye, findings from the Phase 3a REDEFINE-1 trial (NCT05567796) were presented, assessing Novo Nordisk’s fixed-dose combination of cagrilintide 2.4mg and semaglutide 2.4mg (CagriSema) in adults with obesity, defined as a BMI of ≥30kg/m² or ≥27 kg/m² with one or more…

Source: Pharmaceutical Technology